Document is current
Any future updates will be listed below
-
Authors
Sultan, Ihtisham
Waterhouse, David M.
Chopra, Divyan
Lonshteyn, Alexander
Weycker, Derek
Delea, Thomas E.
Stollenwerk, Björn
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 2 October 2024
First Online: 29 October 2024
Declarations
:
: Divyan Chopra and Björn Stollenwerk report being employed by Amgen and holding stocks of the company. Ihtisham Sultan is employed by Amgen and may hold stocks of the company. Alexander Lonshteyn, Derek Weycker, and Thomas E. Delea report being employed by Avalere Health, which has received research funding and consulting fees from Amgen. David M. Waterhouse reports advisory board participation at BMS, AZ, AbbVie, Amgen, Janssen, Eisai, EMD Serono, Merck, Pfizer, Fresenius Kabi, Sanofi, Astellas, Gilead, Takeda, Daiichi Sankyo, and Bayer; receiving consulting fees from BMS, Amgen, Janssen, Merck, Fresenius Kabi, and Novartis; receiving support for attending meetings and/or travel from BMS and Amgen; and receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, AZ, Amgen, Janssen, EMD Serono, Fresenius Kabi, and Sanofi.
: Study data were accessed in compliance with the Health Insurance Portability and Accountability Act of 1996. Because this study used analysis of preexisting, deidentified data, institutional review board approval was not required. Permission to access and utilize data from the Optum Database was obtained through an agreement with Optum.
